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In the opinion of the author, 2013 may someday be seen as an important crossroad in US
psychopharmacology practice. But the prescribers of psychopharmacology in 2013 may not be paying
attention to its potentially bleak future as pharmaceutical companies discontinue the development of new
psychiatric drugs. Instead, psychiatrists may be distracted by the publication of the DSM-5, which has led
to significant controversies in the field of psychiatric diagnosis. While the future and priorities of
psychiatry as a medical discipline are not clear, the use of psychopharmacological drugs in the US
population definitely presents a worrisome paradoxical profile, namely, the obvious undertreatment and
neglect of severe mental illness and the growing overtreatment of minor psychiatric problems.
The author acknowledges that there is an obvious risk in criticizing the current status of US
psychiatry, since his arguments can be used by psychiatry haters or the media to attack his “beloved”
medical discipline. Compared with other disciplines, psychiatry is in a weaker position; it shares with
psychiatric patients the stigma associated with mental illness. Thus, these critiques are written with the
ambivalent feeling of a son who publically criticizes a “sick” mother; he wants her to stop denying and
start facing her problems. This is after many years of thinking that it was not a good idea to openly
criticize things; it would be better to keep things “private” within the family. Finally, the publication of
the DSM-5 plus the denial by US psychiatry’s leadership1 of its obvious limitations and the possibility of
legitimate critiques have led him to take the risk of “publicly” exposing his critical ideas.
PHARMACEUTICAL COMPANIES ARE ABANDONING PSYCHOPHARMACOLOGY
In the past few years, the high-profile pharmaceutical companies have decided to shut down major
research activities in psychopharmacology.2,3 This fact has received little attention in
psychopharmacology journals other than this one.2 Only recently, in 2013, has another journal published a
commentary on this issue.3 In 2012, in an important article, Fibiger explained the position of the
pharmaceutical companies: (1) antipsychotics, antidepressants and anxiolytics were the result of
serendipitous clinical observation while the research of “the past 3 or 4 decades has failed to generate
effective, mechanistically novel psychopharmaceuticals” and (2) “the pharmaceutical industry is now well

2
aware of this fact and has therefore greatly reduced investing.” Fibiger’s recipe for resolving this
situation is very painful and requires: (1) major investments in neuroscience research, (2) humility in the
face of our ignorance, and a (3) willingness to consider fundamental reconceptualizations of psychiatry
itself. One would think that hundreds of psychiatrists worried about the future treatment of their patients
would be commenting on this pessimistic future concerning the development of new and better
psychiatric drugs. This does not appear to be the case. As of June 12, 2013, there were no published
articles quoting Fibiger’s article (http://thomsonreuters.com/web-of-science/). Meanwhile, the leaders of
the National Institute of Mental Health (NIMH) are not worried; they propose to save drug development,4
a slightly less “visionary” view than in 20066 when 21st century psychiatry was only going “to cure”
mental illness. The NIMH differs from pharmaceutical companies in that it has no stock holders requiring
a report after this failure.
THE DISARRAY SURROUNDING THE DSM-5
As this journal is read by many professionals who are not psychiatrists, a discussion of US
psychiatry’s historical “dirty laundry” is needed. Before and during the 1980s, psychiatrists in the US had
multiple problems but “sectarianism” was probably the first.7 In summary, academic psychiatry was
dominated by psychiatrists with a psychoanalytic approach, poor diagnostic skills and no scientific
training.8 A revolt began at Washington University in St. Louis when psychiatrists there reverted back to
the diagnostic criteria used by Kraepelin, a German psychiatrist from early in the 20th century. This was
the so-called neo-Kraepelinian revolution.9 The original neo-Kraepelinians, who described 15 psychiatric
disorders, were worried about validity.10 In a major coup, they “converted” Robert Spitzer, a New York
psychiatrist (New York was probably the sancta sanctorum of psychoanalytic power). Spitzer
outmaneuvered the psychoanalytic establishment and selected many US psychiatrists contaminated by
neo-Kraepelinian beliefs to develop the DSM-III criteria; the DSM-III was published by the American
Psychiatric Association (APA) in 1980. At that time, the DSM-III appeared to be a breath of fresh air that
allowed the development of biological research psychiatry and made US psychiatry the unquestioned
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leader of psychiatry around the world. In the process, a “small” inadvertent problem occurred: Spitzer was
not concerned about the validity of psychiatric diagnostic categories. He had to deal with quarrelsome
psychiatric experts and decided to focus on agreement between experts and interrater reliability.10 In the
process, 265 psychiatric disorders were included in the DSM-III.10 No one was thinking about the
possibility that some of these disorders may not be valid.
After the DSM-III, the APA published several revisions and/or editions leading to the publication
of the DSM-5 in May 2013. The paradoxical situation is that one of the major critics of the DSM-5 is
Allen Frances, who supervised the development of the DSM-IV. Moreover, Frances had to forego using
US psychiatric journals as a means of criticizing the DSM-5. Recently, he has used an international
psychiatric journal11 and an internal medicine journal12 where his recommendation was “to use the DSM-5
cautiously, if at all.” The lack of attention to Frances and the exclusion of his criticisms from key
psychiatric journals appear to the author to be a new form of sectarianism. The author has written articles
detailing this internal fight about psychiatric diagnoses from the scientific point of view12 but this editorial
focuses on the crucial practical relevance of this fight in reference to the prescription of psychiatric drugs
in the US. The author is very worried, as is Frances, that the widening of some psychiatric diagnoses may
lead to even more prescribing of psychiatric drugs in the US to the wrong patients, while those with more
severe mental illness are forgotten. The overdiagnosis of psychiatric disorders in children14 appears
particularly frightening in view of the massive increases of psychopharmacological prescriptions in
children.15 Moreover, the frequent use of antipsychotics16 in children with attention deficit hyperactivity
disorder (ADHD), an off-label use, verifies the idea that psychiatrists may be expected by society to be
the leading experts in controlling behaviors in problematic patients independent of whether these
behaviors are explained by a severe mental illness or not, or whether they really respond to drug
interventions beyond the goal of “sedating” patients who are considered “troublemakers.”
PARADOXES IN US PSYCHOPHARMACOLOGY PRACTICE
Overprescription of psychiatric drugs for minor psychiatric disorders
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By reviewing the literature, Frances concluded that in the US psychotropic drugs taken by 20%
of the US population generate for the pharmaceutical companies $18 billion/year from antipsychotics, $12
billion from antidepressants, and $8 billion from ADHD drugs. Regarding these costs, there are
differences in cost between generic and brand names, so costs may be reduced by progressive changes
from brand names to generics,17, 16 but the most important clinical question is whether diagnosing 20% of
the population taking medications for psychiatric disorders is a number that is too high or too low.
This answer is complex. Frances12 proposes that 15-20% of the US population has minor
psychiatric disorders in which it is hard to distinguish the efficacy of drugs from placebos. If we assume
that this is correct, we may be spending billions on very expensive placebos which, by the way, are not
innocuous. Psychiatric drugs can kill you if you decide to overdose or if the occasional potentially lethal
adverse drug reaction (ADR) occurs when you are taking them as prescribed. Frances appears to get
psychiatrists off the hook by quoting a 2004-05 study19 indicating that 77% of prescriptions for US
psychiatric drugs are not written by psychiatrists, but mainly by primary care physicians. Frances12
believes that US primary care physicians have too little training and insufficient time with the patient to
make an accurate psychiatric diagnosis. I do not know your opinion on this issue, but the author’s primary
care physician, an academic family medicine physician, appears to fit that profile well. The author does
not see an easy solution to this overprescribing by non-psychiatrists and, in his experience, the prescribing
practices of many psychiatrists is not much better. Even if we assume that psychiatrists are less prone to
overprescribe for minor psychiatric disorders that recover spontaneously or with non-specific
interventions, psychiatrists cannot handle psychiatric care for the 15-20% of the US population with
minor psychiatric problems. The other option may not be better, as psychiatrists have no systems or
resources for educating other prescribers about the need to decrease psychiatric medication prescriptions
in psychiatric disorders that may respond to other interventions or placebo.
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To be fair to psychiatry and psychopharmacology, one needs to acknowledge that pharmaceutical
companies have flooded the whole medical market with “lifestyle” drugs20 for the sake of profit, so drug
overprescription is not exclusive to psychiatry and is prevalent across all medical specialties.
Undertreatment of severe mental illness
Frances quotes the statistic12 that 5% of the US population has a severe mental illness. The
psychiatric medications of these patients are usually prescribed by psychiatrists. This prevalence sounds
approximately right, but the sad truth is that there is no standardized definition of severe mental illness.
Most psychiatrists would not disagree that severe mental illness includes schizophrenia, bipolar disorder
and severe cases of depression.21 The author, who is a “quarrelsome” psychiatrist and likes studying the
history of psychiatry and psychopharmacology, would also include an additional syndrome, catatonia,
which has specific treatment responses.22 Including catatonia should not increase the prevalence of severe
mental illness, since in the author’s experience, many US psychiatrists do not know how to diagnose it.
Unfortunately, non-US authors23 report that psychiatrists in other countries also frequently miss the
diagnosis of catatonia. In summary, catatonia should not increase the prevalence of severe mental illness
beyond 5% of the US population.
This brings us back to psychiatry’s dirty laundry. Patients with severe mental illness were
“warehoused” in insane asylums during the 19th century in the civilized areas of the US (and Europe). As
a matter of fact, the APA was founded in 1844 in Philadelphia as the Association of Medical
Superintendents of American Institutions for the Insane. Then, between the 1960s and 1980s
deinstitutionalization took place in the US and the treatment for these deinstitutionalized people with
severe mental illness was poorly funded and separate from the medical treatment of the general
population.24 It may not be familiar to non-psychiatrists that, according to a 2010 review,25 the US houses
three times more severely mentally ill people in prison that in psychiatric hospitals and that 40% of those
hospitalized have been in jail or prison at some time in their lives. Thus, although this has not reached
PubMed and is only recently reaching the media,26 psychiatrists working in the penal system are starting
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to call jails and prisons the “new asylum”. US society as whole is ignoring the fact that this way of
“storing” patients with severe mental illness is not only “inhumane” but very expensive.28 In 2013,
newspapers all over the country reported significant cuts in state mental health budgets that unequivocally
will lead to more people with severe mental illness entering the penal system. Simultaneously, no plans
exist for integrating people with severe mental illness into the new health system that the US is trying to
develop.
TV and other media project the paradoxical viewpoints that sometimes psychiatrists are “evil
controllers” when they are trying to use proven and effective treatments for severe mental illness while at
other times psychiatrists are presented as extraordinarily effective in controlling behaviors not explained
by severe mental illness that in real life do not respond to psychiatric medications. These paradoxical
extremes of undertreatment and overtreatment have also tainted the psychopharmacology practice of the
author, a psychiatrist, within the last year. In the process of educating and supervising residents and
practicing psychiatrists from the public system who consult him, he has found himself continuously
stressing the need for more and better treatment for inpatients with severe mental illness and less
psychopharmacological treatment for outpatients with minor psychiatric problems. The worst distress of
the year was finding that undiagnosed catatonia continues to be lethal in the US. The most frequent
annoyance of the year was reviewing outpatient treatment with residents, which frequently led to the
recommendation to stop medications when the patient was willing to consider that option, or at least
question the psychiatric polypharmacy, which was not justified, due to the lack of an obvious genuine
diagnosis of severe mental illness.
Conclusion
This editorial proposes that 2013 may be viewed in the future as a crossroad for psychiatry, with
paradoxical pressures and messages to practicing psychiatrists including (1) the NIMH’s assurance not to
worry because it can be successful where pharmaceutical companies have failed, since new and better
psychiatric drugs are forthcoming; and (2) the APA’s encouragement to use the DSM-5, which further
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increases the prevalence of mental illness, and its apparent agreement with overprescription of psychiatric
medications to control behaviors even if they are not explained by severe mental illness. Other long-term
pressures and messages emanate from (1) pharmaceutical companies, with the assistance of media, that
continue to encourage drug use for “lifestyle” enhancement; and (2) TV and other media that continue to
project the paradoxical viewpoints that sometimes psychiatrists are “evil controllers” when they are trying
to use proven and effective treatments for severe mental illness while at other times psychiatrists are
presented as extraordinarily effective in controlling behaviors not explained by severe mental illness that
in real life do not respond to psychiatric medications. The most important unheard message which
everyone ignores (including the NIMH and the APA) is that people with severe mental illness are not
receiving the appropriate treatment and that budgets for psychiatric treatment are “evaporating”. As a
result, these patients will increasingly be placed in the penal system, the “new asylum.” If the trend
continues, and there is no sign that it will not, psychiatrists may need to rename themselves “alienists,”25
as in the 19th century. As a matter of fact, if psychiatrists do not consider well their priorities and the
realities of the 21st century, they may be practicing like 19th century alienists with the only improvement
being access to serendipitous drug discoveries from the 20th century.3
Finding solutions for this complex set of problems facing US psychiatry at the beginning of the
21st century is crucial not only for US psychiatry but for world psychiatry, since US psychiatry became
the undisputed world leader with the DSM-III. Meanwhile, European psychiatry appears to have been
asleep29since then, and East Asian psychiatry is only beginning to take its first steps.13 The needs for 1) a
comprehensive research approach which acknowledges that psychiatry is a hybrid discipline,30 and 2) a
greater research focus on the social sciences for defining many of the minor psychiatric disorders listed in
the DSM-5 have been described in articles by the author13 and others.30,31 The need for a comprehensive
approach to better training psychiatrists in what was called descriptive psychopathology and for
modifying psychiatric nosology is described in articles by the author13,29 and others.32 Moreover, a new
21st century nomenclature for describing psychiatric symptoms and disorders using current knowledge
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may be needed.

13,33

Although the author is somewhat pessimistic about psychiatry, he is much more

optimistic about the possibility of improving psychopharmacology. Fifteen years ago, he decided that the
scientific approach had a much more promising future in psychopharmacology than in psychiatry as a
whole, and decided to retrain himself as a pharmacologist by learning more about the pharmacokinetic
and pharmacodynamic mechanisms of each psychiatric drug so as to better personalize treatment in each
patient.34 As psychiatric drugs were mainly a product of serendipity, he is not sure when new
breakthroughs will occur, but he is very sure that we can do a much better job in training psychiatry
residents and other prescribers by combining the evidence-based approach with pharmacokinetic and
pharmacodynamic knowledge in a practical way to better use each psychiatric drug in each patient.35
Moreover, a better job can be done13 in stressing the crucial role of medications (and electroconvulsive
therapy) in severe mental illness versus the limited role and serious consideration of the medication risks
in minor psychiatric disorders, which may respond to other interventions including psychotherapy.
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